| First Author | Yang K | Year | 2024 |
| Journal | Biochem Biophys Res Commun | Volume | 734 |
| Pages | 150593 | PubMed ID | 39217812 |
| Mgi Jnum | J:393597 | Mgi Id | MGI:7766008 |
| Doi | 10.1016/j.bbrc.2024.150593 | Citation | Yang K, et al. (2024) LRRK2 G2019S enhances immune response pathways and aggravates asthma in mouse models. Biochem Biophys Res Commun 734:150593 |
| abstractText | Asthma is a complex inflammatory airway disease that arises from the interplay between genetic predisposition and environmental influences. Leucine-rich repeat kinase 2 (LRRK2), a gene commonly associated with Parkinson's disease, has recently gained attention for its role in immune regulation and inflammation beyond the brain. However, its involvement in asthma has not yet been reported. In this study, we used LRRK2 G2019S transgenic mice and LRRK2 knockout mice to establish asthmatic models to explore LRRK2 impact on asthma. We found that LRRK2 G2019S transgenic mice showed exacerbated airway hyperresponsiveness (AHR) and airway inflammation in asthma mouse models induced by house dust mite. RNA sequencing data unveiled that the LRRK2 G2019S mutation enhanced immune response pathways, including NOD-like receptor, cellular response to interferon beta and activation of innate immune response signaling. Conversely, LRRK2 deficiency attenuated AHR and airway inflammation in the same asthma models. Our study offers new insights into the role of LRRK2 in allergic inflammation and highlights its potential as a therapeutic target for asthma. |
